Insight on VFMCRP, Fresenius Kabi distribution agreement for Veltassa to treat hyperkalemia in China
Posted on20 Nov 2020
Comments0
Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Fresenius Kabi announced an agreement to develop, register and distribute Veltassa for the treatment... Read More